Neuberger Berman Group LLC cut its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 5.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 785,224 shares of the medical research company’s stock after selling 42,506 shares during the quarter. Neuberger Berman Group LLC owned approximately 1.66% of Charles River Laboratories International worth $84,820,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. YorkBridge Wealth Partners LLC grew its position in shares of Charles River Laboratories International by 445.5% in the third quarter. YorkBridge Wealth Partners LLC now owns 1,091 shares of the medical research company’s stock valued at $118,000 after purchasing an additional 891 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its position in Charles River Laboratories International by 69.0% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,342 shares of the medical research company’s stock worth $145,000 after acquiring an additional 548 shares during the last quarter. Advisor Group Inc. boosted its position in Charles River Laboratories International by 159.4% during the third quarter. Advisor Group Inc. now owns 1,538 shares of the medical research company’s stock worth $165,000 after acquiring an additional 945 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Charles River Laboratories International by 12.7% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock worth $181,000 after acquiring an additional 202 shares during the last quarter. Finally, Riverhead Capital Management LLC boosted its position in Charles River Laboratories International by 14.7% during the second quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock worth $195,000 after acquiring an additional 247 shares during the last quarter. Institutional investors and hedge funds own 96.27% of the company’s stock.

Charles River Laboratories International, Inc. (NYSE CRL) opened at $108.08 on Friday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.62 and a current ratio of 1.88. The firm has a market cap of $5,118.88, a P/E ratio of 21.23, a price-to-earnings-growth ratio of 1.72 and a beta of 0.89. Charles River Laboratories International, Inc. has a one year low of $73.81 and a one year high of $119.05.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Thursday, November 9th. The medical research company reported $1.30 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.22 by $0.08. The company had revenue of $464.23 million for the quarter, compared to the consensus estimate of $458.93 million. Charles River Laboratories International had a net margin of 10.72% and a return on equity of 26.58%. Charles River Laboratories International’s revenue was up 9.0% on a year-over-year basis. During the same quarter last year, the firm posted $1.18 earnings per share. equities analysts expect that Charles River Laboratories International, Inc. will post 5.13 EPS for the current year.

A number of analysts recently issued reports on the stock. Argus assumed coverage on shares of Charles River Laboratories International in a research report on Wednesday. They set a “buy” rating and a $120.00 target price on the stock. BidaskClub upgraded shares of Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 22nd. Jefferies Group restated a “buy” rating and set a $120.00 target price on shares of Charles River Laboratories International in a research report on Tuesday, September 12th. Robert W. Baird set a $117.00 target price on shares of Charles River Laboratories International and gave the stock a “buy” rating in a research report on Monday, November 13th. Finally, SunTrust Banks restated a “buy” rating and set a $113.00 target price on shares of Charles River Laboratories International in a research report on Friday, November 17th. Six equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $110.21.

In other Charles River Laboratories International news, insider Bradley Nixon Scharfe sold 1,000,000 shares of the stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $0.27, for a total transaction of $270,000.00. Also, Director C Richard Reese sold 10,227 shares of the stock in a transaction that occurred on Wednesday, December 6th. The stock was sold at an average price of $102.40, for a total transaction of $1,047,244.80. Following the transaction, the director now directly owns 51,444 shares in the company, valued at approximately $5,267,865.60. The disclosure for this sale can be found here. In the last ninety days, insiders have acquired 10,500 shares of company stock worth $2,885 and have sold 1,056,776 shares worth $2,011,952. Company insiders own 2.20% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Neuberger Berman Group LLC Lowers Stake in Charles River Laboratories International, Inc. (CRL)” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/17/neuberger-berman-group-llc-lowers-stake-in-charles-river-laboratories-international-inc-crl.html.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Stock Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related stocks with our FREE daily email newsletter.